BioMedNewsBreaks – GT Biopharma Inc. (NASDAQ: GTBP) Releases Preclinical Results for Prostate Cancer Treatment

GT Biopharma (NASDAQ: GTBP), a clinical-stage biopharmaceutical company focused on disruptive, target-directed natural killer (“NK”) cell engager immunotherapy technologies, has announced preclinical results for its ROR1 (“ROR1”) TriKE(TM) (“TriKE”) product candidate, which is being evaluated as a prospective therapy for the treatment of prostate cancer. The treatment is based on the fact that tyrosine kinase transmembrane receptor ROR1 has been shown to be overexpressed on certain cancer cells and to play a functional role in influencing the metastatic potential of various solid tumor cancers. Through its TriKE treatment, GT Biopharma targets ROR1 on cancer cells, redirecting NK cells to attack and kill cancer cells that express ROR1. The hope is that the therapeutic treatment will limit the metastatic potential and invasiveness of certain solid tumor cancers. In previous preclinical models of prostate cancer, ROR1 TriKE was found to be effective at promoting NK cell killing of multiple prostate cancer cells. “We are pleased to report our ROR1 TriKE has passed this important preclinical milestone, and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells,” said GT Biopharma chairman and CEO Anthony J. Cataldo in the press release. “We plan to evaluate the ROR1 TriKE in additional IND-enabling preclinical studies with the goal of transitioning to a phase I/II clinical trial.”

To view the full press release, visit https://ibn.fm/dnLgT

About GT Biopharma Inc.

GT Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on the company’s proprietary TriKE(TM) (“TriKE”) natural killer (“NK”) cell engager platform. The TriKE platform is designed to activate and redirect the target cell killing abilities of the patient’s NK cells without the need for supplemental ex vivo engineered donor or autologous NK cells, or induced pluripotent stem cells (“iPSC”). GT BioPharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. GT Biopharma’s lead TriKE product candidate, GTB-3550 TriKE, is being evaluated in a multicenter phase I/II trial for the treatment of acute myeloid leukemia, myelodysplastic syndrome and other CD33+ hematopoietic malignancies. For more information about the company, please visit www.GTBioPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork